🇺🇸 Meglumine Sodium Succinate in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Nausea — 2 reports (18.18%)
2. Acute Hepatic Failure — 1 report (9.09%)
3. Ascites — 1 report (9.09%)
4. Aspartate Aminotransferase Increased — 1 report (9.09%)
5. Bilirubin Conjugated Increased — 1 report (9.09%)
6. Cachexia — 1 report (9.09%)
7. Cognitive Disorder — 1 report (9.09%)
8. Condition Aggravated — 1 report (9.09%)
9. Drug Ineffective — 1 report (9.09%)
10. Dyspnoea — 1 report (9.09%)

Source database →

Frequently asked questions

Is Meglumine Sodium Succinate approved in United States?

Meglumine Sodium Succinate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Meglumine Sodium Succinate in United States?

POLYSAN Scientific & Technological Pharmaceutical Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.